With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3282-73-3,Dilauryldimethylammonium Bromide,as a common compound, the synthetic route is as follows.
A mixture of tetrakis(tributylammonium) hydroxygallium(III) naphthalocyaninetetrasulfonate (5.74 g, 3.08 mmol) and didodecyldimethylammonium bromide (5.71 g, 0.012 mol) in methanol (200 mL) was evaporated to half volume with heating under a stream of nitrogen and diluted with water (100 mL). The solid was filtered off and washed with hot water (3¡Á250 mL) and hot acetone/water (50:50, 3¡Á250 mL) and allowed to dry. The solid was then washed further with toluene (2¡Á250 mL) and boiling hexane (250 mL) and dried to give the product as a green powder (7.32 g, 90%).1H NMR (d6-DMSO) delta 0.86 (24H, t, J=6.6 Hz); 1.25 (144H, m); 1.62 (16H, m); 3.20 (16H, m); 4.25 (24H, s); 7.9-11.1 (20H, m).1H NMR (d6-DMSO): delta -0.46 (1H, s); 0.83 (24H, t, J=6.6 Hz); 1.25 (144H, m); 1.60 (16H, m); 3.20 (16H, m); 4.25 (24H, s); 7.9-11.1 (20H, m).UV-Vis-NIR (DMSO): lambdamax 790, 704, 342 nm.
3282-73-3, As the paragraph descriping shows that 3282-73-3 is playing an increasingly important role.
Reference£º
Patent; Silverbrook Research Pty Ltd; US2009/35533; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI